By vgreene, 28 October, 2021 Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection A Randomized Trial
By vgreene, 28 October, 2021 KEY FINDINGS HCQ pre exposure prophylaxis given 1 2x wk did not reduce COVID 19 among healthcare workers
By vgreene, 28 October, 2021 Hydroxychloroquine as Pre exposure Prophylaxis for Coronavirus Disease 2019 COVID 19 in Healthcare Workers A Randomized Trial
By vgreene, 28 October, 2021 Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre exposure SARS CoV 2 Prophylaxis Among Health Care Workers A Randomized Clinical Trial
By vgreene, 28 October, 2021 FDA MedWatch Hydroxychloroquine or Chloroquine for COVID 19 Drug Safety Communication FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems see FDA alert
By vgreene, 28 October, 2021 Proposed mechanism inhibits viral entry and replication via intracellular alkalinization interferes w maturation of viral particles through impaired glycosylation indirect immunomodulatory effects
